Company-reported prevalence
Bezuclastinib
Overview
| Field | Value |
|---|---|
| Drug | Bezuclastinib |
| Indication | Gastrointestinal stromal tumor |
| Disease | Gastrointestinal stromal tumors (GIST); imatinib-resistant and second-line GIST |
| Company | Cogent Biosciences, Inc.; no partner holding rights to bezuclastinib was identified |
| Documents searched | Corporate website, bezuclastinib, pipeline, GIST, and patients and families pages (accessed October 2026); press releases naming bezuclastinib, October 2023 to September 2026; Form 10-K for 2025 (February 2026); Form 10-K for 2024 (February 2025); Form 10-K for 2023 (February 2024); Form 10-Q for the second quarter of 2026 (August 2026); prospectus supplements (November 2025); corporate presentation (September 2026); Peak top-line results presentation (November 2025); Summit full results presentation (December 2025); Summit top-line results presentation (July 2025) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Incidence: Cogent Biosciences Peak top-line results presentation, November 2025
Cited source: 2.1 American Cancer Society 2026; 2.2 Gramza 2009
(opens the full-size image in a new tab)Eligible population (imatinib-resistant GIST): Cogent Biosciences Form 10-K for 2024, February 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
No evidence found.
Global
No evidence found.
Other countries and regions
Incidence: Cogent Biosciences corporate presentation, September 2026
Cited source: 2.1 American Cancer Society 2026; 2.2 Gramza 2009
(opens the full-size image in a new tab)Geography not stated
Eligible population (second-line GIST): Cogent Biosciences corporate presentation, September 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Sources the company cites
American cancer society 2026
Reference as the company lists it, corporate presentation, September 2026
Reference as the company lists it, Peak top-line results presentation, November 2025
Gramza 2009
Reference as the company lists it, corporate presentation, September 2026
Reference as the company lists it, Peak top-line results presentation, November 2025
Passage carrying the nearest figure
References
- American Cancer Society (2026) Key statistics for gastrointestinal stromal tumors (opens in a new tab)
- Cogent Biosciences (2025) Form 10-K for 2024 (opens in a new tab)
- Cogent Biosciences (2025) Peak top-line results presentation, November 2025 (opens in a new tab)
- Cogent Biosciences (2026) corporate presentation, September 2026 (opens in a new tab)
- Gramza 2009 (opens in a new tab)